Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
PHASE III PROGRESS
October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019 - Data Analysis Back, Results Positive.February...
Okay, so What’s Next for Citius Pharma (CTXR) $1.16?
Dawson James Broker/Dealer Updates. Price Target Remains at $7.00.
"OK, So what’s Next? Topline data from the superior efficacy interim analysis should represent the next...
Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.
STREET INSIDER
H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals (NASDAQ: CTXR) to $4.00 (from $1.65) while maintaining a Buy rating.
The analyst commented,...
VIDEO: Dyadic (DYAI) CEO Explains What his Industry is Doing to Defeat Coronavirus (FoxNews).
Jan. 27, 2020 - 5:24 - Dyadic International CEO Mark Emalfarb discusses what’s being done to stop the spread of coronavirus and to...
Could Dyadic (DYAI) $5.75 Provide a Solution to Help Mass Produce Vaccines to Battle...
Dyadic (DYAI) has developed a biomanufacturing technology platform, nicknamed C1 which helps to speed the development, lower the manufacturing cost and potentially improve the...
CoronaVirus Watch List Stocks in the News (Bloomberg, Benzinga).
INITIAL WATCHLIST: CoronaVirus Watch List | Superbug Stock Review
Aethlon Medical, Inc. (NASDAQ: AEMD) $2.40 Alpha Pro Tech, Ltd. (NYSE: APT) $6.00AstraZeneca plc (NYSE: AZN) $49BioCryst Pharmaceuticals, Inc.'s (NASDAQ: BCRX) $2.80 Cerus Corporation (NASDAQ: CERS)...
Biotech 5 Pack. 5 Biotech Stocks We Expect to Double in 2020.
Our First Newsletter of 2020, We Come out Swinging!
Yes, you read it right. Five of our favorite Biotech stocks that have the potential to...
New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.
Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the Biotech Stock...
Citius Pharma (CTXR) Corporate Presentation (Jan 2020).
In the above graphic, the catheter can get infected by bacteria and most typically see evidence of the infection (see gross graphic below) at...
Oramed (ORMP) $5.24, Focused on Pill Form Insulin. Is China First?
New technology could revolutionize market of 500 million diabetes patients (i24 News).
LIVE CHART
Oramed Pharmaceuticals (ORMP) developed insulin capsule that can be consumed orally
A new...
Latest article
Fairchild Gold (FAIR.V) Advances Towards Drilling.
Fairchild Gold Advances Toward Drilling at Nevada Titan as Geophysics Sharpens Porphyry Targeting
Vancouver, British Columbia and Las Vegas, Nevada--(Newsfile Corp. - August 21, 2026)...
Hecla Mining (HL) $20.75 – Rips 33% Higher, on Incredible Numbers.
Shareholders Celebrate $4 Billion Gain in Market Value, in a Couple Weeks! And we'll drink to that!
When we added Hecla Mining (HL) to the...
A Turnaround at Mitesco Coming? Mitesco Moves Into Mini-Data Centers.
Last Round (turnaround that is) worked great, back in 2019, Trading From $0.02 to $0.50. And no, we Didn't Sell a Single Share (waa)....
